Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Neoplasms × patritumab deruxtecan × Clear all

Phase

Status

Recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 4 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Lung Neoplasms 3 Esophageal Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Stomach Neoplasms 1 Solid Tumor, Adult 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms 1 Melanoma 1 Head and Neck Neoplasms 1 Gastrointestinal Neoplasms 1 Endometrial Neoplasms 1 Breast Cancer Metastatic 1

Interventions

pembrolizumab 35 Blood Specimen Collection 34 Bevacizumab 18 Standard of Care 16 Radiotherapy 15 Carboplatin 15 Surveys and Questionnaires 13 Paclitaxel 13 Nivolumab 13 Exercise 13 Drug Therapy 11 Cisplatin 11 atezolizumab 10 Docetaxel 10 Dexamethasone 10 Cyclophosphamide 10 Fluorouracil 9 Trastuzumab 8 Pemetrexed 8 Leucovorin 8 Cetuximab 8 pertuzumab 7 olaparib 7 Temozolomide 7 Oxaliplatin 7 Observation 7 Irinotecan 7 Interviews as Topic 7 Radiosurgery 6 Panitumumab 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06941272 2026-03-13

MK-9999-01C

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡